Conceptualization and treatment of negative symptoms in schizophrenia

Sonali Sarkar, Kiley Hillner, Dawn I Velligan, Sonali Sarkar, Kiley Hillner, Dawn I Velligan

Abstract

Negative symptoms of schizophrenia including social withdrawal, diminished affective response, lack of interest, poor social drive, and decreased sense of purpose or goal directed activity predict poor functional outcomes for patients with schizophrenia. They may develop and be maintained as a result of structural and functional brain abnormalities, particularly associated with dopamine reward pathways and by environmental and psychosocial factors such as self-defeating cognitions and the relief from overstimulation that accompanies withdrawal from social and role functioning. Negative symptoms are more difficult to treat than the positive symptoms of schizophrenia and represent an unmet therapeutic need for large numbers of patients with schizophrenia. While antipsychotic medications to treat the symptoms of schizophrenia have been around for decades, they have done little to address the significant functional impairments in the disorder that are associated with negative symptoms. Negative symptoms and the resulting loss in productivity are responsible for much of the world-wide personal and economic burden of schizophrenia. Pharmacologic treatments may be somewhat successful in treating secondary causes of negative symptoms, such as antipsychotic side effects and depression. However, in the United States there are no currently approved treatments for severe and persistent negative symptoms (PNS) that are not responsive to treatments for secondary causes. Pharmacotherapy and psychosocial treatments are currently being developed and tested with severe and PNS as their primary targets. Academia, clinicians, the pharmaceutical industry, research funders, payers and regulators will need to work together to pursue novel treatments to address this major public health issue.

Keywords: Functional outcomes; Motivation; Negative symptoms; Schizophrenia; Treatment.

Figures

Figure 1
Figure 1
Maintenance loop for the negative symptoms of schizophrenia.

References

    1. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67–76.
    1. Saarni SI, Viertiö S, Perälä J, Koskinen S, Lönnqvist J, Suvisaari J. Quality of life of people with schizophrenia, bipolar disorder and other psychotic disorders. Br J Psychiatry. 2010;197:386–394.
    1. Barnes TR, Leeson VC, Mutsatsa SH, Watt HC, Hutton SB, Joyce EM. Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. Br J Psychiatry. 2008;193:203–209.
    1. Anthony WA, Blanch A. Supported employment for persons who are psychiatrically disabled: An historical and conceptual perspective. Psychosocial Rehabilitation Journal. 1987;11:5–23.
    1. Wyatt RJ, Henter I, Leary MC, Taylor E. An economic evaluation of schizophrenia 1991. Soc Psychiatry Psychiatr Epidemiol. 1995;30:196–205.
    1. Souetre E. Economic evaluation in schizophrenia. Neuropsychobiology. 1997;35:67–69.
    1. Trauer T, Duckmanton RA, Chiu E. Estimation of costs of public psychiatric treatment. Psychiatr Serv. 1998;49:440–442.
    1. Insel TR. Assessing the economic costs of serious mental illness. Am J Psychiatry. 2008;165:663–665.
    1. Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005;66:1122–1129.
    1. Rössler W, Salize HJ, van Os J, Riecher-Rössler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 2005;15:399–409.
    1. Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull. 2007;33:1013–1022.
    1. Liemburg E, Castelein S, Stewart R, van der Gaag M, Aleman A, Knegtering H, Risk G. Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts. J Psychiatr Res. 2013;47:718–725.
    1. Velligan DI, Maglinte GA, Sierra C, Martin ML. Corey-Lisle. Novel assessment tool for patients with schizophrenia: Development of the daily activity report. Presented at The International Society for CNS Clinical Trials and Methodology; Philadelphia, Pennsylvania; September 30-October 2, 2013
    1. Messinger JW, Trémeau F, Antonius D, Mendelsohn E, Prudent V, Stanford AD, Malaspina D. Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research. Clin Psychol Rev. 2011;31:161–168.
    1. Stahl SM, Buckley PF. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr Scand. 2007;115:4–11.
    1. Boonstra N, Klaassen R, Sytema S, Marshall M, De Haan L, Wunderink L, Wiersma D. Duration of untreated psychosis and negative symptoms--a systematic review and meta-analysis of individual patient data. Schizophr Res. 2012;142:12–19.
    1. Chang WC, Hui CL, Tang JY, Wong GH, Lam MM, Chan SK, Chen EY. Persistent negative symptoms in first-episode schizophrenia: a prospective three-year follow-up study. Schizophr Res. 2011;133:22–28.
    1. Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG, Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res. 2012;137:147–150.
    1. Kurtz MM, Moberg PJ, Ragland JD, Gur RC, Gur RE. Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study. Schizophr Bull. 2005;31:167–174.
    1. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005;162:495–506.
    1. Lencz T, Smith CW, Auther A, Correll CU, Cornblatt B. Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr Res. 2004;68:37–48.
    1. Valmaggia LR, Stahl D, Yung AR, Nelson B, Fusar-Poli P, McGorry PD, McGuire PK. Negative psychotic symptoms and impaired role functioning predict transition outcomes in the at-risk mental state: a latent class cluster analysis study. Psychol Med. 2013;43:2311–2325.
    1. Hovington CL, Bodnar M, Joober R, Malla AK, Lepage M. Identifying persistent negative symptoms in first episode psychosis. BMC Psychiatry. 2012;12:224.
    1. Bambole V, Shah N, Sonavane S, Johnston M, Shrivastava A. Study of negatives symptoms in first episode schizophrenia. Open Journal of Psychiatry. 2013;3:323–328.
    1. Makinen J, Miettunen J, Isohanni M, Koponen H. Negative symptoms in schizophrenia-a review. Nord J Psychiat. 2008;62:334–341.
    1. Arango C, Buchanan R, Kirkpatrick B, Carpenter W. The deficit syndrome in schizophrenia: Implications for the treatment of negative symptoms. Eur Psychiatry. 2004;19:21–26.
    1. Carpenter WT, Kirkpatrick B. The heterogeneity of the long-term course of schizophrenia. Schizophrenia Bulletin. 1988;14:645–652.
    1. Fenton WS, Wyatt RJ, McGlashan TH. Risk factors for spontaneous dyskinesia in schizophrenia. Arch Gen Psychiatry. 1994;51:643–650.
    1. Tiryaki A, Yazici MK, Anil AE, Kabakçi E, Karaağaoğlu E, Göğüş A. Reexamination of the characteristics of the deficit schizophrenia patients. Eur Arch Psychiatry Clin Neurosci. 2003;253:221–227.
    1. Mayerhoff DI, Loebel AD, Alvir JM, Szymanski SR, Geisler SH, Borenstein M, Lieberman JA. The deficit state in first-episode schizophrenia. Am J Psychiatry. 1994;151:1417–1422.
    1. Bottlender R, Wegner U, Wittmann J, Strauss A, Möller HJ. Deficit syndromes in schizophrenic patients 15 years after their first hospitalisation: preliminary results of a follow-up study. Eur Arch Psychiatry Clin Neurosci. 1999;249 Suppl 4:27–36.
    1. Kirkpatrick B, Amador XF, Flaum M, Yale SA, Gorman JM, Carpenter WT, Tohen M, McGlashan T. The deficit syndrome in the DSM-IV Field Trial: I. Alcohol and other drug abuse. Schizophr Res. 1996;20:69–77.
    1. Buchanan RW, Gold JM. Negative symptoms: diagnosis, treatment and prognosis. Int Clin Psychopharmacol. 1996;11 Suppl 2:3–11.
    1. Horan WP, Blanchard JJ. Neurocognitive, social, and emotional dysfunction in deficit syndrome schizophrenia. Schizophr Res. 2003;65:125–137.
    1. Tek C, Kirkpatrick B, Buchanan RW. A five-year followup study of deficit and nondeficit schizophrenia. Schizophr Res. 2001;49:253–260.
    1. Buchanan RW, Strauss ME, Kirkpatrick B, Holstein C, Breier A, Carpenter WT. Neuropsychological impairments in deficit vs nondeficit forms of schizophrenia. Arch Gen Psychiatry. 1994;51:804–811.
    1. Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN, Carpenter WT. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry. 1992;49:522–530.
    1. Buchanan RW, Breier A, Kirkpatrick B, Elkashef A, Munson RC, Gellad F, Carpenter WT. Structural abnormalities in deficit and nondeficit schizophrenia. Am J Psychiatry. 1993;150:59–65.
    1. Grover S, Kulhara P. Deficit schizophrenia: Concept and validity. Indian J Psychiatry. 2008;50:61–66.
    1. Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32:214–219.
    1. Alphs L. An industry perspective on the NIMH consensus statement on negative symptoms. Schizophr Bull. 2006;32:225–230.
    1. Colibazzi T, Wexler BE, Bansal R, Hao X, Liu J, Sanchez-Peña J, Corcoran C, Lieberman JA, Peterson BS. Anatomical abnormalities in gray and white matter of the cortical surface in persons with schizophrenia. PLoS One. 2013;8:e55783.
    1. Ananth H, Popescu I, Critchley HD, Good CD, Frackowiak RS, Dolan RJ. Cortical and subcortical gray matter abnormalities in schizophrenia determined through structural magnetic resonance imaging with optimized volumetric voxel-based morphometry. Am J Psychiatry. 2002;159:1497–1505.
    1. Eisenberger NI, Berkman ET, Inagaki TK, Rameson LT, Mashal NM, Irwin MR. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol Psychiatry. 2010;68:748–754.
    1. Juckel G, Schlagenhauf F, Koslowski M, Wüstenberg T, Villringer A, Knutson B, Wrase J, Heinz A. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage. 2006;29:409–416.
    1. Laviolette SR. Dopamine modulation of emotional processing in cortical and subcortical neural circuits: Evidence for a final common pathway in schizophrenia? Schizophr Bull. 2007;33:971–981.
    1. Guillin O, Abi-Dargham A, Laruelle M. Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol. 2007;78:1–39.
    1. Dandash O, Fornito A, Lee J, Keefe RS, Chee MW, Adcock RA, Pantelis C, Wood SJ, Harrison BJ. Altered striatal functional connectivity in subjects with an at-risk mental state for psychosis. Schizophr Bull. 2014;40:904–913.
    1. Andreasen NC, Ehrhardt JC, Swayze VW, Alliger RJ, Yuh WT, Cohen G, Ziebell S. Magnetic resonance imaging of the brain in schizophrenia. The pathophysiologic significance of structural abnormalities. Arch Gen Psychiatry. 1990;47:35–44.
    1. Breier A, Buchanan RW, Elkashef A, Munson RC, Kirkpatrick B, Gellad F. Brain morphology and schizophrenia. A magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures. Arch Gen Psychiatry. 1992;49:921–926.
    1. Turetsky B, Cowell PE, Gur RC, Grossman RI, Shtasel DL, Gur RE. Frontal and temporal lobe brain volumes in schizophrenia. Relationship to symptoms and clinical subtype. Arch Gen Psychiatry. 1995;52:1061–1070.
    1. Lim KO, Tew W, Kushner M, Chow K, Matsumoto B, DeLisi LE. Cortical gray matter volume deficit in patients with first-episode schizophrenia. Am J Psychiatry. 1996;153:1548–1553.
    1. Chua SE, Wright IC, Poline JB, Liddle PF, Murray RM, Frackowiak RS, Friston KJ, McGuire PK. Grey matter correlates of syndromes in schizophrenia: A semi-automated analysis of structural magnetic resonance images. Br J Psychiatry. 1997;170:406–410.
    1. Ho BC, Andreasen NC, Nopoulos P, Arndt S, Magnotta V, Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry. 2003;60:585–594.
    1. Flashman LA, Green MF. Review of cognition and brain structure in schizophrenia: profiles, longitudinal course, and effects of treatment. Psychiatr Clin North Am. 2004;27:1–18, vii.
    1. Roth RM, Flashman LA, Saykin AJ, McAllister TW, Vidaver R. Apathy in schizophrenia: reduced frontal lobe volume and neuropsychological deficits. Am J Psychiatry. 2004;161:157–159.
    1. Kim JJ, Crespo-Facorro B, Andreasen NC, O’Leary DS, Magnotta V, Nopoulos P. Morphology of the lateral superior temporal gyrus in neuroleptic naïve patients with schizophrenia: relationship to symptoms. Schizophr Research. 2003;60:173–181.
    1. Millan MJ, Fone K, Steckler T, Horan WP. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 2014;24:645–692.
    1. Beck AT, Rector NA, Stolar N, Grant PM. Schizophrenia: Cognitive theory, research, and therapy. New York: The Guilford Press; 2009.
    1. Velligan D, Maples N, Roberts DL, Medellin EM. Integrated Psychosocial Treatment for Negative Symptoms. American Journal of Psychiatric Rehabilitation. 2014;17:1–19.
    1. Granholm E, Ben-Zeev D, Link PC. Social disinterest attitudes and group cognitive-behavioral social skills training for functional disability in schizophrenia. Schizophr Bull. 2009;35:874–883.
    1. Grant PM, Beck AT. Defeatist beliefs as a mediator of cognitive impairment, negative symptoms, and functioning in schizophrenia. Schizophr Bull. 2009;35:798–806.
    1. Gard DE, Kring AM, Gard MG, Horan WP, Green MF. Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr Res. 2007;93:253–260.
    1. Bustillo J, Lauriello J, Horan W, Keith S. The psychosocial treatment of schizophrenia: an update. Am J Psychiatry. 2001;158:163–175.
    1. Weisman AG, Nuechterlein KH, Goldstein MJ, Snyder KS. Controllability perceptions and reactions to symptoms of schizophrenia: a within-family comparison of relatives with high and low expressed emotion. J Abnorm Psychol. 2000;109:167–171.
    1. Alphs L, Hill C, Cazorla P. Psychometric evaluation of the four-item Negative Symptom Assessment (NSA-4) in schizophrenic patients with predominant negative symptoms. New Clinical Drug Evaluation Unit, 47th Annual Meeting; Boca Raton, FL, 2007.
    1. Forbes C, Blanchard JJ, Bennett M, Horan WP, Kring A, Gur R. Initial development and preliminary validation of a new negative symptom measure: the Clinical Assessment Interview for Negative Symptoms (CAINS) Schizophr Res. 2010;124:36–42.
    1. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276.
    1. Kirkpatrick B, Strauss GP, Nguyen L, Fischer BA, Daniel DG, Cienfuegos A, Marder SR. The brief negative symptom scale: psychometric properties. Schizophr Bull. 2011;37:300–305.
    1. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS) Iowa City: The University of Iowa; 1984.
    1. Velligan DI, Roberts D, Mintz J, Maples N, Li X, Medellin E, Brown M. A randomized pilot study of MOtiVation and Enhancement (MOVE) Training for negative symptoms in schizophrenia. Schizophr Res. 2015;165:175–180.
    1. Velligan DI, Lopez L, Castillo DA, Manaugh B, Milam AC, Miller AL. Interrater reliability of using brief standardized outcome measures in a community mental health setting. Psychiatr Serv. 2011;62:558–560.
    1. Buckley PF, Stahl SM. Pharmacologic treatment of negative symptoms of schizophrenia: therapeutic opportunity or Cul-de-sac? Acta Psychiatrica Scandinavica. 2007;115:93–100.
    1. Yassini M, Shariat N, Nadi M, Amini F, Vafaee M. The effects of bupropion on negative symptoms in schizophrenia. Iran J Pharm Res. 2014;13:1227–1233.
    1. Rummel C, Kissling W, Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev. 2006;(3):CD005581.
    1. Velligan DI, Alphs LD. Negative symptoms in schizophrenia: the importance of identification and treatment. Psychiatric Times. 2008;25:12.
    1. Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F. Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry. 1995;166:68–72.
    1. Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry. 1997;170:18–22.
    1. Danion JM, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry. 1999;156:610–616.
    1. Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36:94–103.
    1. Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef EA, Ostland M, Wallace TL, Knoflach F, Dorflinger E, Wettstein JG, et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry. 2014;71:637–646.
    1. Kingwell K. Schizophrenia drug gets negative results for negative symptoms. Nat Rev Drug Discov. 2014;13:244–245.
    1. Coyle JT, Basu A, Benneyworth M, Balu D, Konopaske G. Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. Novel Antischizophrenia Treatments. Berlin Heidelberg: Springer; 2012. pp. 267–295.
    1. Roffman JL, Lamberti JS, Achtyes E, Macklin EA, Galendez GC, Raeke LH, Silverstein NJ, Smoller JW, Hill M, Goff DC. Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry. 2013;70:481–489.
    1. Arango C, Garibaldi G, Marder SR. Pharmacological approaches to treating negative symptoms: a review of clinical trials. Schizophr Res. 2013;150:346–352.
    1. Kern RS, Glynn SM, Horan WP, Marder SR. Psychosocial treatments to promote functional recovery in schizophrenia. Schizophr Bull. 2009;35:347–361.
    1. Patterson TL, Leeuwenkamp OR. Adjunctive psychosocial therapies for the treatment of schizophrenia. Schizophr Res. 2008;100:108–119.
    1. Grant PM, Reisweber J, Luther L, Brinen AP, Beck AT. Successfully breaking a 20-year cycle of hospitalizations with recovery-oriented cognitive therapy for schizophrenia. Psychol Serv. 2014;11:125–133.
    1. Valmaggia LR, van der Gaag M, Tarrier N, Pijnenborg M, Slooff CJ. Cognitive-behavioural therapy for refractory psychotic symptoms of schizophrenia resistant to atypical antipsychotic medication. Randomised controlled trial. Br J Psychiatry. 2005;186:324–330.
    1. Röhricht F, Priebe S. Effect of body-oriented psychological therapy on negative symptoms in schizophrenia: a randomized controlled trial. Psychol Med. 2006;36:669–678.
    1. Hogarty GE, Flesher S, Ulrich R, Carter M, Greenwald D, Pogue-Geile M, Kechavan M, Cooley S, DiBarry AL, Garrett A, et al. Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior. Arch Gen Psychiatry. 2004;61:866–876.
    1. Eack SM, Greenwald DP, Hogarty SS, Cooley SJ, DiBarry AL, Montrose DM, Keshavan MS. Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial. Psychiatr Serv. 2009;60:1468–1476.
    1. Demily C, Franck N. Cognitive remediation: a promising tool for the treatment of schizophrenia. Expert Rev Neurother. 2008;8:1029–1036.
    1. Bellack AS. Skills training for people with severe mental illness. Psychiatr Rehabil J. 2004;27:375–391.
    1. Heinssen RK, Liberman RP, Kopelowicz A. Psychosocial skills training for schizophrenia: lessons from the laboratory. Schizophr Bull. 2000;26:21–46.
    1. Draper ML, Stutes DS, Maples NJ, Velligan DI. Cognitive adaptation training for outpatients with schizophrenia. J Clin Psychol. 2009;65:842–853.
    1. Velligan DI, Diamond PM, Mintz J, Maples N, Li X, Zeber J, Ereshefsky L, Lam YW, Castillo D, Miller AL. The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophr Bull. 2008;34:483–493.
    1. Velligan DI, Bow-Thomas CC, Huntzinger C, Ritch J, Ledbetter N, Prihoda TJ, Miller AL. Randomized controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia. Am J Psychiatry. 2000;157:1317–1323.
    1. Velligan DI, Diamond PM, Maples NJ, Mintz J, Li X, Glahn DC, Miller AL. Comparing the efficacy of interventions that use environmental supports to improve outcomes in patients with schizophrenia. Schizophr Res. 2008;102:312–319.
    1. Lessof MH, Youlten LJ, Heavey D, Kemeny DM, Dollery C. Local mediator release in bee venom anaphylaxis. Clin Exp Allergy. 1989;19:231–232.
    1. Velligan DI, Alphs L, Lancaster S, Morlock R, Mintz J. Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophrenia. Psychiatry Res. 2009;169:97–100.
    1. Roberts DL, Penn DL. Social cognition and interaction training (SCIT) for outpatients with schizophrenia: a preliminary study. Psychiatry Res. 2009;166:141–147.
    1. Liberman RP, Glynn S, Blair KE, Ross D, Marder SR. In vivo amplified skills training: promoting generalization of independent living skills for clients with schizophrenia. Psychiatry. 2002;65:137–155.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere